Amarin fishes for another CFO as downsizing takes hold; CureVac makes a deal, then lines up Novartis exec to lead development

Tom Reilly

→ Mired in flagging sales for Vascepa, the harsh realities of the current climate in biotech have hit Amarin as they slice 40% of the workforce — the majority of those cuts coming from the US commercial team. And the resignation of…